CXCL12 and acute myeloid leukemia: Our findings suggest that, for significant AML growth inhibition, therapeutic strategies targeting CXCR4 should be aimed at inhibiting CXCR4 signaling rather than blocking the CXCR4-CXCL12 interaction, which restrains AML development.